Drugs / GLS4
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04551261 | Jan → Mar 2021 | chronic hepatitis B virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03662568 | Jun → Jul 2018 | chronic hepatitis B virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT04147208 | Feb 2019 → Jun 2022 | chronic hepatitis B virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | Met primary |
| Phase 2 | NCT03638076 | Jul 2017 → Nov 2018 | chronic hepatitis B virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLS4 | “Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg twice daily for 48 weeks.” NCT03638076 ↗ |
| Action | Inhibit | “inhibits HBV replication by interfering with assembly and disassembly of the virus nucleocapsid” PMID 39988055 ↗ Feb 2025 |
| Modality | Other / unclassified | “GLS4 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator” PMID 39988055 ↗ Feb 2025 |
| Route | Oral | “Administered GLS4 120 mg orally three times daily in fed state” NCT03662568 ↗ |